Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
Abstract Background Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62–66%). Cyclophosphamide is considered a seco...
Main Authors: | Johanna P. van Gemert, Inge A. H. van den Berk, Esther J. Nossent, Leo M. A. Heunks, Rene E. Jonkers, Alexander P. Vlaar, Peter I. Bonta |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-021-01615-2 |
Similar Items
-
Platelet-Rich Plasma Ameliorates Cyclophosphamide-Induced Acute Interstitial Cystitis/Painful Bladder Syndrome in a Rat Model
by: Yung-Hsiang Chen, et al.
Published: (2020-06-01) -
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases
by: Valeria Nucera, et al.
Published: (2021-01-01) -
Characterization and Validation of a Chronic Model of Cyclophosphamide-Induced Interstitial Cystitis/Bladder Pain Syndrome in Rats
by: Céline Augé, et al.
Published: (2020-08-01) -
Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
by: Mehdi Mirsaeidi, et al.
Published: (2019-10-01) -
Current therapeutic strategies in connective tissue disease-related interstitial lung disease: introduction to the special issue
by: Gian Luca Erre, et al.
Published: (2021-01-01)